 Azathioprine
"Azathioprine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
| Descriptor ID |
D001379
|
| MeSH Number(s) |
D02.886.759.111 D03.438.759.534.090 D13.570.900.111
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azathioprine".
Below are MeSH descriptors whose meaning is more specific than "Azathioprine".
This graph shows the total number of publications written about "Azathioprine" by people in this website by year, and whether "Azathioprine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 1 | 1 | | 1982 | 1 | 0 | 1 | | 1983 | 0 | 1 | 1 | | 1984 | 0 | 1 | 1 | | 1985 | 1 | 0 | 1 | | 1986 | 0 | 1 | 1 | | 1987 | 0 | 2 | 2 | | 1989 | 1 | 1 | 2 | | 1992 | 0 | 2 | 2 | | 1993 | 1 | 5 | 6 | | 1994 | 0 | 1 | 1 | | 1995 | 2 | 2 | 4 | | 1996 | 0 | 3 | 3 | | 1997 | 0 | 6 | 6 | | 1998 | 1 | 3 | 4 | | 1999 | 1 | 3 | 4 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 3 | 3 | | 2002 | 1 | 0 | 1 | | 2004 | 2 | 2 | 4 | | 2005 | 2 | 1 | 3 | | 2006 | 1 | 3 | 4 | | 2007 | 1 | 1 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 1 | 2 | 3 | | 2010 | 1 | 3 | 4 | | 2011 | 1 | 0 | 1 | | 2013 | 6 | 1 | 7 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 1 | 2 | | 2018 | 3 | 1 | 4 | | 2020 | 1 | 1 | 2 | | 2021 | 2 | 3 | 5 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Azathioprine" by people in Profiles.
-
Daniel LL, Dickson AL, Zanussi JT, Miller-Fleming TW, Straub PS, Wei WQ, Plummer WD, Dupont WD, Liu G, Anandi P, Reese TS, Birdwell KA, Kawai VK, Hung AM, Cox NJ, Feng Q, Stein CM, Chung CP. Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity. Clin Transl Sci. 2022 04; 15(4):859-865.
-
Sattler L, Hanauer SB, Malter L. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep. 2021 Dec 16; 23(12):30.
-
Dickson AL, Daniel LL, Zanussi J, Dale Plummer W, Wei WQ, Liu G, Reese T, Anandi P, Birdwell KA, Kawai V, Cox NJ, Dupont WD, Hung AM, Feng Q, Stein CM, Chung CP. TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results. Clin Pharmacol Ther. 2022 01; 111(1):263-271.
-
Buisson A, Nancey S, Manlay L, Rubin DT, Hebuterne X, Pariente B, Fumery M, Laharie D, Roblin X, Bommelaer G, Pereira B, Peyrin-Biroulet L, Vuitton L. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterol J. 2021 06; 9(5):552-560.
-
Kastin D, Siegel M, Anderson R, Aronsohn A. IgG 4 Autoimmune Hepatitis Presenting as Idiopathic Hypereosinophilia Syndrome. Hepatology. 2021 04; 73(4):1615-1617.
-
Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, Kim M, Berdofe A, Radhakrishnan M, Jung E, Sandrock AW, Smirnakis K, Popescu C, de Moor C. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, Cohen RD, Chambers CD, Sandborn WJ. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021 03; 160(4):1131-1139.
-
Anandi P, Dickson AL, Feng Q, Wei WQ, Dupont WD, Plummer D, Liu G, Octaria R, Barker KA, Kawai VK, Birdwell K, Cox NJ, Hung A, Stein CM, Chung CP. Combining clinical and candidate gene data into a risk score for azathioprine-associated leukopenia in routine clinical practice. Pharmacogenomics J. 2020 10; 20(5):736-745.
-
Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1.
-
Hanauer SB, Sandborn WJ, Lichtenstein GR. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|